Published in J Infect Dis on April 01, 1999
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med (2009) 3.94
Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest (2009) 3.89
Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis (2014) 3.66
Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest (2009) 3.55
Progressive CD4+ central memory T cell decline results in CD4+ effector memory insufficiency and overt disease in chronic SIV infection. J Exp Med (2007) 3.45
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog (2009) 3.35
Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog (2010) 3.28
Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol (2007) 3.24
HIV infection and the gastrointestinal immune system. Mucosal Immunol (2008) 3.14
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med (2001) 3.05
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev (2001) 2.87
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet (2006) 2.86
Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol (2012) 2.84
Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis (2012) 2.64
Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog (2010) 2.57
Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol (2005) 2.48
Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med (2013) 2.47
Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS (2011) 2.43
Understanding the benign nature of SIV infection in natural hosts. J Clin Invest (2007) 2.43
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis (2011) 2.35
Microbial translocation across the GI tract. Annu Rev Immunol (2012) 2.30
Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin Microbiol Rev (2006) 2.28
Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis (2014) 2.26
Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLoS Comput Biol (2007) 2.25
Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis (2013) 2.23
Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol (2008) 2.23
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol (2007) 2.19
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis (2011) 2.10
Microbial translocation, immune activation, and HIV disease. Trends Microbiol (2012) 2.07
Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog (2013) 2.06
Predictors of disease progression in HIV infection: a review. AIDS Res Ther (2007) 2.05
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood (2012) 2.03
Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol (2013) 2.01
HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci U S A (2008) 1.95
Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Microbiol Rev (2004) 1.95
T cell dynamics and the response to HAART in a cohort of HIV-1-infected elite suppressors. Clin Infect Dis (2009) 1.94
Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS (2010) 1.94
The multicenter AIDS Cohort Study, 1983 to …. Public Health (2011) 1.93
Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood (2012) 1.91
HIV-1 Nef: at the crossroads. Retrovirology (2008) 1.88
Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol (2008) 1.86
Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One (2008) 1.83
Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS (2010) 1.83
Cutting edge: Experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion. J Immunol (2008) 1.82
Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin Microbiol Rev (2013) 1.82
CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection. Nat Med (2009) 1.81
Reduced inflammation and lymphoid tissue immunopathology in rhesus macaques receiving anti-tumor necrosis factor treatment during primary simian immunodeficiency virus infection. J Infect Dis (2012) 1.80
Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol (2010) 1.78
Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol (2007) 1.77
Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol (2007) 1.74
Turnover of lymphocytes and conceptual paradigms in HIV infection. J Clin Invest (2003) 1.69
T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis (2011) 1.64
Revisiting immune exhaustion during HIV infection. Curr HIV/AIDS Rep (2011) 1.62
Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol (2008) 1.62
HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One (2008) 1.61
Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J Clin Invest (2011) 1.61
Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest (2010) 1.59
The level of monocyte turnover predicts disease progression in the macaque model of AIDS. Blood (2009) 1.59
CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev (2013) 1.58
Immune reconstitution in human immunodeficiency virus type 1-infected children with different virological responses to anti-retroviral therapy. Clin Exp Immunol (2007) 1.55
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
The mucosal barrier and immune activation in HIV pathogenesis. Curr Opin HIV AIDS (2008) 1.54
Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis (2010) 1.53
Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity (2010) 1.50
Is the high virulence of HIV-1 an unfortunate coincidence of primate lentiviral evolution? Nat Rev Microbiol (2009) 1.50
Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.50
Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol (2008) 1.49
A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. PLoS Pathog (2010) 1.48
TRIM protein-mediated regulation of inflammatory and innate immune signaling and its association with antiretroviral activity. J Virol (2012) 1.47
Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol (2008) 1.47
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
Th-1-type cytotoxic CD8+ T-lymphocyte responses to simian immunodeficiency virus (SIV) are a consistent feature of natural SIV infection in sooty mangabeys. J Virol (2006) 1.44
Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS. J Virol (2007) 1.44
Paucity of CD4+ CCR5+ T cells may prevent transmission of simian immunodeficiency virus in natural nonhuman primate hosts by breast-feeding. J Virol (2008) 1.44
A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One (2011) 1.43
Disruption of intestinal CD4+ T cell homeostasis is a key marker of systemic CD4+ T cell activation in HIV-infected individuals. J Immunol (2010) 1.42
Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.40
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS One (2012) 1.39
HIV-associated chronic immune activation. Immunol Rev (2013) 1.38
Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers. J Virol (2011) 1.38
Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest (2011) 1.37
Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol (2007) 1.35
Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest (2013) 1.35
Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis (2003) 1.33
Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci (2013) 1.33
Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One (2010) 1.32
Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol (2010) 1.32
Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol (2009) 1.31
CD127 and CD25 expression defines CD4+ T cell subsets that are differentially depleted during HIV infection. J Immunol (2008) 1.31
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol (1987) 17.36
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med (1996) 10.49
Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature (2000) 9.80
The Mouse Genome Database (MGD): integrating biology with the genome. Nucleic Acids Res (2004) 8.91
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Laboratory investigation of a multistate food-borne outbreak of Escherichia coli O157:H7 by using pulsed-field gel electrophoresis and phage typing. J Clin Microbiol (1994) 8.37
The Mouse Genome Database (MGD): from genes to mice--a community resource for mouse biology. Nucleic Acids Res (2005) 8.19
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med (1990) 6.94
Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ. Cell (1996) 6.87
KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med (1996) 5.96
Expression of a Delta homologue in prospective neurons in the chick. Nature (1995) 5.73
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35
Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 5.30
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med (1999) 5.18
Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol (1991) 5.09
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science (1994) 4.84
Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med (1996) 4.57
A nuclear cap binding protein complex involved in pre-mRNA splicing. Cell (1994) 4.56
Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study. Lancet (1987) 4.33
Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science (2001) 4.25
The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med (1990) 4.25
Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med (1989) 4.20
Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N Engl J Med (1996) 4.13
Rapid detection of herpes-simplex-virus DNA in cerebrospinal fluid of patients with herpes simplex encephalitis. Lancet (1990) 4.12
A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med (1992) 4.05
Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (1993) 3.91
A cap-binding protein complex mediating U snRNA export. Nature (1995) 3.89
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses (1991) 3.78
Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis (2000) 3.73
Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol (1989) 3.59
Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A (2004) 3.57
Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology (1993) 3.53
The acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.49
Primary neurogenesis in Xenopus embryos regulated by a homologue of the Drosophila neurogenic gene Delta. Nature (1995) 3.39
The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med (1992) 3.32
Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature (1995) 3.27
Attachment of local health authority staff to general practices. 1. A study in three county boroughs with special reference to health visiting. Nurs Times (1968) 3.21
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med (1998) 3.15
Actin cables and epidermal movement in embryonic wound healing. Nature (1992) 3.11
T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol (1989) 3.00
A method for measurement of antibiotics in human interstitial fluid. J Infect Dis (1972) 2.99
Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS (2000) 2.99
Prevalence of HIV infection among former commercial plasma donors in rural eastern China. Health Policy Plan (2001) 2.94
A1, Cw7, B8, DR3 HLA antigen combination associated with rapid decline of T-helper lymphocytes in HIV-1 infection. A report from the Multicenter AIDS Cohort Study. Lancet (1990) 2.89
Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med (1981) 2.89
Notch signalling and the synchronization of the somite segmentation clock. Nature (2000) 2.84
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas (1996) 2.74
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol (1992) 2.67
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
The Peckham Health Centre, "PEP", and the concept of general practice during the 1930s and 1940s. Med Hist (1983) 2.65
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med (1984) 2.60
Pediatric telephone triage protocols: standardized decisionmaking or a false sense of security? Ann Emerg Med (1999) 2.58
Human papillomavirus types 6 and 11 mRNAs from genital condylomata acuminata. J Virol (1987) 2.57
Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia. Am J Med (1990) 2.56
Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr (2001) 2.51
Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol (2001) 2.50
Quality control in the flow cytometric measurement of T-lymphocyte subsets: the multicenter AIDS cohort study experience. The Multicenter AIDS Cohort Study Group. Clin Immunol Immunopathol (1990) 2.50
Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation (2001) 2.46
Relation between sexual practices and T-cell subsets in homosexually active men. Lancet (1983) 2.46
Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. AIDS (1990) 2.46
CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 2.45
HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil. N Engl J Med (1989) 2.45
Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot. Evidence from a cohort of homosexual men. Ann Intern Med (1989) 2.44
HIV-1 infection in commercial plasma donors in China. Lancet (1995) 2.42
A modified assay of neutrophil function: use of lysostaphin to differentiate defective phagocytosis from impaired intracellular killing. J Lab Clin Med (1971) 2.40
Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci U S A (1999) 2.39
Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS (1998) 2.33
Nonfatal childhood injuries: a survey at the Children's Hospital of eastern Ontario. CMAJ (1992) 2.32
Restoration of squamous mucosa after ablation of Barrett's esophageal epithelium. Gastroenterology (1993) 2.32
Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci U S A (2001) 2.29
High resolution microendoscopy for classification of colorectal polyps. Endoscopy (2013) 2.29